| Name of study |
Isfahan Cohort Study (ICS), baseline survey of the Isfahan Healthy Heart Program (IHHP) |
| Inclusion criteria |
Participants of the baseline survey of the Isfahan Healthy Heart Program, a community trial for prevention and control of CVD |
| Exclusion criteria |
Diabetes at baseline |
| Notes |
Baseline data for prediabetic cohort at baseline becoming diabetic at follow‐up (N = 131) |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Study participation: description of source population or population of interest |
Low risk |
Yes |
| Study participation: description of glycaemic status at baseline |
Low risk |
Yes |
| Study participation: adequate description of sampling frame & recruitment |
Low risk |
Yes |
| Study participation: adequate description of period & recruitment place |
Low risk |
Yes |
| Study participation: adequate description of inclusion & exclusion criteria |
Low risk |
Inclusion and exclusion criteria described |
| Study attrition: description of attempts to collect information on participants who dropped out |
Low risk |
Yes |
| Study attrition: reasons for loss to follow‐up provided |
Unclear risk |
Scarce data |
| Study attrition: adequate description of participants lost to follow‐up |
Unclear risk |
Scarce data |
| Study attrition: no important differences between participants who completed the study and those who did not |
Low risk |
Yes |
| Glycaemic status measurement: provision of clear definition or description of glycaemic status |
Low risk |
Yes |
| Glycaemic status measurement: valid and reliable method of glycaemic status measurement |
Low risk |
Yes |
| Glycaemic status measurement: continuous variables reported or appropriate cut points used |
Low risk |
IFG: FPG ≥ 5.5 and < 7.0; IGT: 2‐h OGTT ≥ 7.8 and < 11.1 |
| Glycaemic status measurement: same method and setting of measurement of the glycaemic status for all study participants |
Low risk |
Yes |
| Outcome measurement: clear definition of the outcome provided |
Low risk |
FPG > 7.0; 2‐h OGTT > 11.1; IFG/IGT; antihyperglycaemic medication |
| Outcome measurement: method of outcome measurement used valid & reliable |
Low risk |
Yes |
| Outcome measurement: same method & setting of outcome measurement for all study participants |
Low risk |
Yes |
| Study confounding: important confounders measured |
Unclear risk |
Some covariates measured (see Appendix 16 and Appendix 17) |
| Study confounding: clear definitions of important confounders provided |
Low risk |
Yes |
| Study confounding: measurement of confounders valid & reliable |
Low risk |
Yes |
| Study confounding: same method & setting for measurements of confounders for all study participants |
Low risk |
Yes |
| Study confounding: appropriate methods used if missing confounder data imputed |
Low risk |
Stochastic regression methods |
| Study confounding: important potential confounders accounted for in study design |
Unclear risk |
Some covariates included (see Appendix 16 and Appendix 17) |
| Study confounding: important potential confounders accounted for in the analysis |
Unclear risk |
Some covariates analysed (see Appendix 16 and Appendix 17) |
| Statistical analysis & reporting: sufficient presentation of data to assess adequacy of the analytic strategy |
Low risk |
Cumulative incidence, incidence rate, odds ratio |
| Statistical analysis & reporting: the statistical model is adequate for the design of the study |
Low risk |
Multivariate logistic regression |
